

# ISLB ANNUAL CONGRESS

## **VIRTUAL** 30 October 2020



### *Special Workshop*

#### **SENSITIVITY , SPECIFICITY AND LOW COST : KEYS FOR THE CLINICAL IMPLEMENTATION OF CTCs DETECTION**

October 29th 2020 - 6:30pm CET Time

**Dr Ma Jose Serrano**

Hospital U Virgen de Las Nieves.Granada. Spain

**Dr Rocio Ramos Medina**

Translational Oncology Lab. Hospital General Universitario Gregorio Marañón, Spain

### **Welcome Remarks/Opening Ceremony**

**Dr Massimo Cristofanilli and Dr Christian Rolfo**

Introducing ISLB, CROH the Official Journal of ISLB

**MODULE: Session 1**  
**CTCs clinical application: a mirage or a reality?**  
 Chair: Dr Emilio Alba

Keynote Presentation

**Dr Evi Lianidou - University of Athens, Greece**  
 Computational Analysis of Circulating Tumor Cells

PRESENTATION	SPEAKER	INSTITUTE
Isolation of CTC using biological and physical properties of CTC. Analyses of results	Dr. Clotilde Costa Nogueira	Roche-Chus. Santiago de Compostela, Spain
Advances in the clinical application of molecular characterization of CTCs in Cancer	Dr. Bruno Paiva	Universidad de Navarra, Spain
CTCs 2020: How far we are from routine use in clinical?	Dr. Rita Zamarchi	Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
“In-depth characterization of CTCs and liquid biopsies using highly multiplexed detection via mass cytometry and microfluidic technologies”	Dr. Roberto Spada	Senior Business Development Manager, Fluidigm, Italy
Integration of cytological score on circulating cancer cells in cancer risk models for clinical use	Dra. Natalia Malara	University Magna Graecia, Italy

**MODULE: Session 2**  
**ISLB – ISEV joint session in Extracellular Vesicles**  
Chairs: Dr. Simona Taverna

**Keynote Presentation**

**Dr Raghu Kalluri - MD Anderson Cancer Center, USA**  
From the bench to Regulatory Approval (IDE, 501k)

PRESENTATION	SPEAKER	INSTITUTE
From the Isolation to characterization: do we have a standard?	Dr. Susana Garcia	Spanish National Cancer Research Center
Roles of extracellular vesicles in cancer cell biology - therapeutic and diagnostic implications	Dr. Manu Carollo	Oxford Brookes University, UK
Mesenchymal Stem Cell-derived Extracellular Vesicles, a novel Tool in Regenerative Medicine	Dr. Bernd Giebel	University Hospital Essen, Germany

### MODULE: Session 3

#### Investigating nucleic acid detection and their significance in solid tumors: ctDNA and the new entry ctRNA

Chair: Dr. Luis Montuenga

### Keynote Presentation

**Dr David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA**

The revolution of ctDNA in Cancer

PRESENTATION	SPEAKER	INSTITUTE
ctDNA based minimal residual disease detection and recurrence surveillance	Dr Tenna Vesterman Henriksen	Aarhus University Hospital / Skejby, Denmark
Problems in reporting and interpretation	Dr. Luis Paz-Ares	Hospital Universitario 12 de Octubre, Madrid, Spain
CtDNA and clonal haematopoiesis.	Dr. Christian Rolfo	University of Maryland, USA
Circulatory Nucleic Acid Based Applications in Metastatic Prostate Cancer	Dr. Manish Kohli	Huntsman Cancer Institute- University of Utah, USA
VALUE study experience: use of liquid biopsy in advanced NSCLC in Canada	Dr Natasha Leighl	Princess Margaret Hospital, Toronto, Canada
Cell-free Tumor Monitoring in Clinical Practice - from Value Proposition to Financial Sustainability	Jochen Lennerz, MD, Ph.D	Massachusetts General Hospital, Boston

--	--	--

**MODULE: Session 4**

**Keynote Presentation**  
**Dr Joan Seoane - Vall d'Hebrón Institute of Oncology, Spain**  
Liquid biopsy in brain cancer. Getting beyond blood

**ISLB – International Liquid Biopsy Alliance (ILBA)**

**Chair: Dr Juan José Diaz Mochon**

PRESENTATION	SPEAKER	INSTITUTE
EU/IMI Cancer-ID & European Liquid Biopsy Society (ELBS)	Dr. Klaus Pantel	Körperschaft des öffentlichen Rechts; Gerichtsstand, Germany
The importance of advocacy in Liquid Biopsy	Mrs. Valerie Fraser	Breast Cancer International Consortium, USA
Blood Profiling Atlas Consortium (BloodPac)	Lauren Leiman	Executive Director of BloodPAC, USA

## MODULE: Session 5

### Liquid Biopsy in practicality

Chairs: Dr. Gil-Bazo

PRESENTATION	SPEAKER	INSTITUTE
CTC and ctDNA clinical utility in metastatic breast cancer	Dr. Jean-Yves Pierga	Institut Curie, France
Preanalytical Conditions and Quality Control Steps for ctDNA analyses	Dr. Eloisa Jantus	Fundación Hospital General Universitario de Valencia · Molecular Oncology, Spain
Young investigator communication	Dr. Laure Sorber	University of Antwerp, Belgium
Longitudinal monitoring of advanced HER2+ breast cancer by liquid biopsy	Dr. Mateo Allegretti	IRCSS Regina Elena National Cancer Institute, Italy
How Residual Disease and Recurrence (RDR) Testing using Liquid Biopsy is Changing Clinical Trial Design	Dr. Nitzan Rosenfeld PhD	University of Cambridge, CRUK Cambridge Institute and Chief Scientific Officer, Inivata
Utility of liquid biopsies in the detection of residual disease and recurrence in early breast cancer	Dr. Isaac Garcia-Murillas PhD	The Institute of Cancer Research, London UK
Update on Clinical Applications of Circulating Tumor DNA Analysis	Dr. Theresa Rich	Sr. Medical Science Liaison, Guardant, USA

## MODULE: Session 6

### Keynote Presentation

**Dr David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA**

Liquid biopsy and Immunotherapy: bTMB and beyond

### Cancer Interception, Screening and Minimal Residual Disease

Chairs: Dr Santiago Viteri

PRESENTATION	SPEAKER	INSTITUTE
Cancer Interception a new opportunity for Liquid Biopsy	Dr Maria Jose Serrano	Hospital U Virgen de Las Nieves.Granada. Spain
CTCs in Cancer Interception	Dr. Bernardino Alcázar	Hospital de Alta Resolución de Loja, Spain
Role of ctDNA in C.I. and Screening	Dr. Alain .R. Thierry	Université de Sciences Montpellier, France
Applications of Mutation-Agnostic Detection of Circulating Tumor DNA Using Methylation Profiling	Dr Janku Filip	MD Anderson, USA

**MODULE: Session 7**  
**Liquid biopsy beyond ctDNA & other fluids**  
**Chair: Dr Umberto Malapelle**

PRESENTATION	SPEAKER	INSTITUTE
Urine as promising biomarker source for cancer detection	Stephanie Jordaens	Biomedical Scientist at Novosanis PhD Student at University of Antwerp Belgium
Tumor Educated platelets and beyond	Dr. Carmen Garrido	University of Granada, Spain
Towards the development of IVD tests based on circulating miRNAs for personalized precision medicine	Dr. José Luis García	Universidad de Valencia, Spain
Monitoring Clinical Outcomes with Liquid Biopsies (cfDNA and cfRNA)	Dr. Luis Raez	Memorial Healthcare System, USA
Platelets and the circulome	Dr. Elisa Giovannetti	Vrije Universiteit Amsterdam, Holland